Advanced Clinical partners to advance recruitment in Alzheimer’s trials

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags: Alzheimer's disease, Alzheimer, Neurology, CRO, Clinical trial, Clinical trial management, Clinical trial costs, Recruitment, Clinical operations

Advanced Clinical is partnering with Cognitive Clinical Trials to overcome recruitment road blocks in Alzheimer’s clinical trials and expedite research through patient centric model.

Cognitive Clinical Trials (CCT) specializes in streamlining solutions for clinical trial sponsors, sites, and patients. The partnership will give Advanced Clinical, a contract research organization (CRO), accelerated research by improving patients’ access to trials and bolstering recruitment and retention.

Through CCT’s proprietary clinical research model for Alzheimer’s disease clinical research, the partnership will take on the obstacles that are commonly faced​ in this research field.

Julie Ross, president of Advanced Clinical told us that the main benefit of the model is “bringing the research to the patients instead of requiring the patients/caregivers to find a clinic or University.”

CCT embeds clinical research infrastructure within senior living communities. This infrastructure includes a fully staffed clinic, clinical research coordinators, and research professionals.

“Since patient recruitment and patient retention remain two of the largest challenges in completing trials,”​ the partnership will bring an effective approach to these challenges since patients are evaluated within their communities, explained Ross.

Ross told us that this model goes behind patient-centricity, decreasing start-up timelines and providing a central point of contact for all business operations. 

“With our partnership, we can offer rapid study start-up across 9 locations dedicated to Alzheimer’s research and as CCT continues to expand, start-up timelines will get more efficient,”​ said Ross.

New design to pair with new drugs

Currently, 92 new medicines are in clinical development to treat Alzheimer’s disease, according to a report​ by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Seventy-five percent of the drugs in Phase II or III are potentially disease modifying​, aiming to delay the onset of the degenerative disease.

There are currently more than 400 Alzheimer’s studies​ recruiting on ClinicalTrials.gov with roughly 50,000 volunteers needed. 

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars